GRAIL Securities Fraud Class Action
GRAIL · GRAIL common stock and the NHS-Galleri cancer screening trial · Ongoing Litigation
About this case
A securities fraud class action alleges that GRAIL and certain executives misled investors about the design, progress, follow-up period, and efficacy of the NHS-Galleri cancer screening trial while allegedly withholding information about limitations that affected its primary endpoint. The lawsuit has been filed and is described as pending, with an August 4, 2026, deadline for investors to seek appointment as lead plaintiff.
Case overview
- Defendant company
- GRAIL
- Product or service
- GRAIL common stock and the NHS-Galleri cancer screening trial
- Court case number
- 4:26-cv-05428
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Lead plaintiff application
Participation information
Lead plaintiff application
Investors who purchased or acquired GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered significant losses, were described as potentially eligible to seek appointment as lead plaintiff.
Investors were instructed to contact Hagens Berman to ask the court to appoint them as lead plaintiff.
- Type
- Lead Plaintiff
- Status
- Deadline passed
- Reported proof requirement
- Unclear
Sources
- GRAIL Securities Fraud Class Action
Barchart.com ·
- GRAIL Investor Securities Fraud Class Action
Barchart.com ·